Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Celltrion Wins Race For High-Concentration Adalimumab

Receives Positive CHMP Opinion For 100mg/ml Biosimilar To Humira

Dec 11 2020

• By David Wallace

Man Winning Race — Celltrion expects to receive the first approval for a high-concentration adalimumab biosimilar • Source: Shutterstock

Related Content

Pfizer Will Not Launch EU Adalimumab

Jan 29 2020

Alvotech Files Higher-Strength Adalimumab In US And EU

Nov 19 2020

Four adalimumabs compete in EU

Oct 26 2018

Celltrion Pushes ‘Biobetters’ Concept With Remsima SC

Nov 15 2019

Celltrion Reports Positive Data For High-Concentration Adalimumab

Nov 06 2020

Additional Topics

Europe Approvals Biosimilars BioPharmaceutical

More from Products

More from Generics Bulletin

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.